Tumor heterogeneity, clonal evolution, and therapy resistance: an opportunity for multitargeting therapy

Area of Science:

• Oncology
• Cancer Biology
• Molecular Chaperones

Background:

• Tumor heterogeneity is a hallmark of cancer, stemming from factors like nutrient gradients, normal cell infiltration, and hierarchical cell populations.
• Cancer arises from tumor-initiating cells (TICs), often cancer stem cells (CSCs), which exhibit resistance to therapy and high metastatic potential.
• Key cancer properties, including oncogene activation, treatment resistance, and metastasis, are linked to the molecular chaperone heat shock protein 90 (Hsp90).

Purpose of the Study:

• To explore the therapeutic potential of targeting heterogeneous tumor cell populations.
• To investigate the role of Hsp90 in maintaining cancer stem cell properties and driving tumor evolution.
• To evaluate Hsp90 inhibitors as a strategy to inactivate TICs and prevent the emergence of new cancer phenotypes.

Main Methods:

• Review of existing literature on tumor heterogeneity, cancer stem cells, and Hsp90 function.
• Discussion of the mechanisms by which Hsp90 influences cancer cell properties and evolution.
• Conceptual framework for targeting Hsp90 in heterogeneous tumors.

Main Results:

• Hsp90 is crucial for the survival and function of cancer stem cells.
• Hsp90 inhibition can disrupt the hierarchical structure of tumors.
• Targeting Hsp90 may prevent the development of treatment resistance and metastasis.

Conclusions:

• Hsp90 is a critical regulator of tumor-initiating cells and cancer evolution.
• Hsp90 inhibitors represent a promising therapeutic strategy for combating heterogeneous tumors.
• Targeting Hsp90 could overcome treatment resistance and inhibit metastatic spread.